A short hairpin RNA-based adjuvant targeting NF-κB repressor IκBα promotes migration of dermal dendritic cells to draining lymph nodes and antitumor CTL responses induced by DNA vaccination

Vaccine

Volumn 35, Issue 33, 2017, Pages 4148-4154

  Gálvez Cancino, Felipe ^a   Roco, Jonathan ^a   Rojas Colonelli, Nicole ^a   Flores, Camila ^a   Murgas, Paola ^a   Cruz Gómez, Sebastián ^a   Oyarce, César ^a   Varas Godoy, Manuel ^b   Sauma, Daniela ^c   Lladser, Alvaro ^a  

^a Fundacion Ciencia para la Vida   (Chile)

^b UNIVERSIDAD DE LOS ANDES   (Chile)

^c UNIVERSITY OF CHILE   (Chile)

Author keywords

Cancer vaccine; Dendritic cell; DNA vaccine; Genetic adjuvant; I B ; NF B inhibitor

Indexed keywords

B7 ANTIGEN; CD103 ANTIGEN; CD11B ANTIGEN; CHEMOKINE RECEPTOR CCR7; DNA VACCINE; DOPACHROME TAUTOMERASE; I KAPPA B KINASE ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LANGERIN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; SHORT HAIRPIN RNA; CANCER VACCINE; IMMUNOLOGICAL ADJUVANT; SMALL INTERFERING RNA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN EXPRESSION; ARTICLE; CD8+ T LYMPHOCYTE; CELL MIGRATION; CONTROLLED STUDY; CROSS PRESENTATION; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; DNA IMMUNIZATION; ELECTROPORATION; ENZYME DEGRADATION; ENZYME PHOSPHORYLATION; ENZYME SYNTHESIS; GENE EXPRESSION REGULATION; IN VITRO STUDY; IN VIVO STUDY; INNATE IMMUNITY; LUNG CANCER; LYMPHOCYTE ACTIVATION; MELANOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; RNA INTERFERENCE; SKIN CELL; UPREGULATION; ANIMAL; ANTAGONISTS AND INHIBITORS; C57BL MOUSE; CELL MOTION; DISEASE MODEL; IMMUNOLOGY; LANGERHANS CELL; LUNG; LYMPH NODE; METABOLISM; PATHOLOGY; PHYSIOLOGY; TREATMENT OUTCOME; VACCINATION;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; CANCER VACCINES; CELL MOVEMENT; DISEASE MODELS, ANIMAL; LANGERHANS CELLS; LUNG; LYMPH NODES; MELANOMA; MICE, INBRED C57BL; NF-KAPPAB INHIBITOR ALPHA; RNA, SMALL INTERFERING; T-LYMPHOCYTES, CYTOTOXIC; TREATMENT OUTCOME; VACCINATION; VACCINES, DNA;

EID: 85021795199     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2017.06.041     Document Type: Article

References (46)

1. Couzin-Frankel, J., Breakthrough of the year 2013 Cancer immunotherapy. Science 342:6165 (2013), 1432–1433.
2. Topalian, S.L., et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 366:26 (2012), 2443–2454.
3. Valsecchi, M.E., Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med, 373(13), 2015, 1270.
4. Chimeric Antigen Receptor-Modified, T Cells in chronic lymphoid leukemia; chimeric antigen receptor-modified T cells for acute lymphoid leukemia; chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med, 374(10), 2016, 998.
5. Tacken, P.J., Figdor, C.G., Targeted antigen delivery and activation of dendritic cells in vivo: steps towards cost effective vaccines. Semin Immunol 23:1 (2011), 12–20.
6. Henri, S., et al. CD207+ CD103+ dermal dendritic cells cross-present keratinocyte-derived antigens irrespective of the presence of Langerhans cells. J Exp Med 207:1 (2010), 189–206.
7. Bedoui, S., et al. Cross-presentation of viral and self antigens by skin-derived CD103+ dendritic cells. Nat Immunol 10:5 (2009), 488–495.
8. Ginhoux, F., et al. The origin and development of nonlymphoid tissue CD103+ DCs. J Exp Med 206:13 (2009), 3115–3130.
9. Lladser, A., et al. DAI (DLM-1/ZBP1) as a genetic adjuvant for DNA vaccines that promotes effective antitumor CTL immunity. Mol Ther 19:3 (2011), 594–601.
10. Lamolinara, A., et al. Intradermal DNA electroporation induces cellular and humoral immune response and confers protection against HER2/neu tumor. J Immunol Res, 2015, 2015, 159145.
11. Kulkarni, V., et al. DNA vaccination by intradermal electroporation induces long-lasting immune responses in rhesus macaques. J Med Primatol 43:5 (2014), 329–340.
12. Luxembourg, A., Evans, C.F., Hannaman, D., Electroporation-based DNA immunisation: translation to the clinic. Expert Opin Biol Ther 7:11 (2007), 1647–1664.
13. Ahlen, G., et al. In vivo electroporation enhances the immunogenicity of hepatitis C virus nonstructural 3/4A DNA by increased local DNA uptake, protein expression, inflammation, and infiltration of CD3+ T cells. J Immunol 179:7 (2007), 4741–4753.
14. Babiuk, S., et al. Increased gene expression and inflammatory cell infiltration caused by electroporation are both important for improving the efficacy of DNA vaccines. J Biotechnol 110:1 (2004), 1–10.
15. Ligtenberg, M.A., et al. NF-kappaB activation during intradermal DNA vaccination is essential for eliciting tumor protective antigen-specific CTL responses. Hum Vaccin Immunother 9:10 (2013), 2189–2195.
16. Ishii, K.J., et al. TANK-binding kinase-1 delineates innate and adaptive immune responses to DNA vaccines. Nature 451:7179 (2008), 725–729.
17. Takeshita, F., et al. Toll-like receptor adaptor molecules enhance DNA-raised adaptive immune responses against influenza and tumors through activation of innate immunity. J Virol 80:13 (2006), 6218–6224.
18. Sasaki, S., et al. Regulation of DNA-raised immune responses by cotransfected interferon regulatory factors. J Virol 76:13 (2002), 6652–6659.
19. Baeuerle, P.A., Baltimore, D., I kappa B: a specific inhibitor of the NF-kappa B transcription factor. Science 242:4878 (1988), 540–546.
20. Hoffmann, A., Baltimore, D., Circuitry of nuclear factor kappaB signaling. Immunol Rev 210 (2006), 171–186.
21. Sun, S.C., et al. NF-kappa B controls expression of inhibitor I kappa B alpha: evidence for an inducible autoregulatory pathway. Science 259:5103 (1993), 1912–1915.
22. Shen, L., et al. Silencing of SOCS1 enhances antigen presentation by dendritic cells and antigen-specific anti-tumor immunity. Nat Biotechnol 22:12 (2004), 1546–1553.
23. Yen, M.C., et al. A novel cancer therapy by skin delivery of indoleamine 2,3-dioxygenase siRNA. Clin Cancer Res 15:2 (2009), 641–649.
24. Wang, S.T., et al. RNA interference-mediated silencing of Foxo3 in antigen-presenting cells as a strategy for the enhancement of DNA vaccine potency. Gene Ther 18:4 (2011), 372–383.
25. Boyle, J.S., et al. DNA immunization: induction of higher avidity antibody and effect of route on T cell cytotoxicity. Proc Natl Acad Sci U S A 94:26 (1997), 14626–14631.
26. Bronte, V., et al. Genetic vaccination with “self” tyrosinase-related protein 2 causes melanoma eradication but not vitiligo. Cancer Res 60:2 (2000), 253–258.
27. Rubinson, D.A., et al. A lentivirus-based system to functionally silence genes in primary mammalian cells, stem cells and transgenic mice by RNA interference. Nat Genet 33:3 (2003), 401–406.
28. Martin, C.S., et al. Dual luminescence-based reporter gene assay for luciferase and beta-galactosidase. Biotechniques 21:3 (1996), 520–524.
29. van Hogerlinden, M., et al. Squamous cell carcinomas and increased apoptosis in skin with inhibited Rel/nuclear factor-kappaB signaling. Cancer Res 59:14 (1999), 3299–3303.
30. Herrada, A.A., et al. Harnessing DNA-induced immune responses for improving cancer vaccines. Hum Vaccin Immunother 8:11 (2012), 1682–1693.
31. Roos, A.K., et al. Skin electroporation: effects on transgene expression, DNA persistence and local tissue environment. PLoS One, 4(9), 2009, e7226.
32. Larghi, P., et al. The p50 subunit of NF-kappaB orchestrates dendritic cell lifespan and activation of adaptive immunity. PLoS One, 7(9), 2012, e45279.
33. Rescigno, M., et al. Dendritic cell survival and maturation are regulated by different signaling pathways. J Exp Med 188:11 (1998), 2175–2180.
34. Marques, J.T., Williams, B.R., Activation of the mammalian immune system by siRNAs. Nat Biotechnol 23:11 (2005), 1399–1405.
35. Yoshimura, S., et al. Role of NFkappaB in antigen presentation and development of regulatory T cells elucidated by treatment of dendritic cells with the proteasome inhibitor PSI. Eur J Immunol 31:6 (2001), 1883–1893.
36. Baratin, M., et al. Homeostatic NF-kappaB signaling in steady-state migratory dendritic cells regulates immune homeostasis and tolerance. Immunity 42:4 (2015), 627–639.
37. Elnekave, M., et al. Directly transfected langerin+ dermal dendritic cells potentiate CD8+ T cell responses following intradermal plasmid DNA immunization. J Immunol 185:6 (2010), 3463–3471.
38. Bourke, C.D., et al. Epidermal keratinocytes initiate wound healing and pro-inflammatory immune responses following percutaneous schistosome infection. Int J Parasitol 45:4 (2015), 215–224.
39. Teunissen, M.B., et al. Interleukin-17 and interferon-gamma synergize in the enhancement of proinflammatory cytokine production by human keratinocytes. J Invest Dermatol 111:4 (1998), 645–649.
40. Albanesi, C., Cavani, A., Girolomoni, G., IL-17 is produced by nickel-specific T lymphocytes and regulates ICAM-1 expression and chemokine production in human keratinocytes: synergistic or antagonist effects with IFN-gamma and TNF-alpha. J Immunol 162:1 (1999), 494–502.
41. Braff, M.H., Di Nardo, A., Gallo, R.L., Keratinocytes store the antimicrobial peptide cathelicidin in lamellar bodies. J Invest Dermatol 124:2 (2005), 394–400.
42. Mempel, M., et al. Toll-like receptor expression in human keratinocytes: nuclear factor kappaB controlled gene activation by Staphylococcus aureus is toll-like receptor 2 but not toll-like receptor 4 or platelet activating factor receptor dependent. J Invest Dermatol 121:6 (2003), 1389–1396.
43. Li, Z.J., et al. Roles of TLR7 in activation of NF-kappaB signaling of keratinocytes by imiquimod. PLoS One, 8(10), 2013, e77159.
44. Mitchell, D.A., et al. Tetanus toxoid and CCL3 improve dendritic cell vaccines in mice and glioblastoma patients. Nature 519:7543 (2015), 366–369.
45. MartIn-Fontecha, A., et al. Regulation of dendritic cell migration to the draining lymph node: impact on T lymphocyte traffic and priming. J Exp Med 198:4 (2003), 615–621.
46. Shigihara, T., et al. CXCL10 DNA vaccination prevents spontaneous diabetes through enhanced beta cell proliferation in NOD mice. J Immunol 175:12 (2005), 8401–8408.